celecoxib has been researched along with Hypoxia in 9 studies
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "SD rats were randomly divided into normal control group (A), hypoxic hypercapnic group (B), hypoxic hypercapnia+ celecoxib group (C)." | 7.77 | [Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats]. ( Huang, YP; Liu, LJ; Wang, LX; Xie, YP; Zeng, HH, 2011) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 7.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "SD rats were randomly divided into normal control group (A), hypoxic hypercapnic group (B), hypoxic hypercapnia+ celecoxib group (C)." | 3.77 | [Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats]. ( Huang, YP; Liu, LJ; Wang, LX; Xie, YP; Zeng, HH, 2011) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 3.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has recently emerged from clinical and animal studies." | 1.46 | Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea. ( Almendros, I; Campillo, N; Farré, R; Gozal, D; Montserrat, JM; Navajas, D; Nonaka, PN; Picado, C; Roca-Ferrer, J; Torres, M; Vilaseca, A, 2017) |
| " However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control." | 1.33 | Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. ( Olivo, M; Soo, KC; Yee, KK, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beaudin, AE | 2 |
| Pun, M | 2 |
| Yang, C | 1 |
| Nicholl, DD | 1 |
| Steinback, CD | 1 |
| Slater, DM | 1 |
| Wynne-Edwards, KE | 2 |
| Hanly, PJ | 2 |
| Ahmed, SB | 2 |
| Poulin, MJ | 2 |
| Waltz, X | 1 |
| Anderson, TJ | 1 |
| Campillo, N | 1 |
| Torres, M | 1 |
| Vilaseca, A | 1 |
| Nonaka, PN | 1 |
| Gozal, D | 1 |
| Roca-Ferrer, J | 1 |
| Picado, C | 1 |
| Montserrat, JM | 1 |
| Farré, R | 1 |
| Navajas, D | 1 |
| Almendros, I | 1 |
| Zeng, HH | 1 |
| Liu, LJ | 1 |
| Huang, YP | 1 |
| Xie, YP | 1 |
| Wang, LX | 1 |
| Su, CL | 1 |
| Yuan, DW | 1 |
| Chiang, LL | 1 |
| Lee, HL | 1 |
| Chen, KH | 1 |
| Wang, D | 1 |
| Lin, E | 1 |
| Morris, JS | 1 |
| Ayers, GD | 1 |
| Yee, KK | 1 |
| Soo, KC | 1 |
| Olivo, M | 1 |
| Wang, J | 1 |
| Wu, K | 1 |
| Bai, F | 1 |
| Zhai, H | 1 |
| Xie, H | 1 |
| Du, Y | 1 |
| Liang, J | 1 |
| Han, S | 1 |
| Chen, Y | 1 |
| Lin, T | 1 |
| Fan, D | 1 |
| Fenton, BM | 1 |
| Paoni, SF | 1 |
| Grimwood, B | 1 |
| Ding, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans[NCT01280006] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Hypoxia
| Article | Year |
|---|---|
Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea.
Topics: Adult; Blood Pressure; Celecoxib; Cerebrovascular Circulation; Cross-Over Studies; Cyclooxygenase 1; | 2014 |
Human intermittent hypoxia-induced respiratory plasticity is not caused by inflammation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Double-Blind Method; | 2015 |
7 other studies available for celecoxib and Hypoxia
| Article | Year |
|---|---|
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.
Topics: Animals; Celecoxib; Cell Polarity; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Model | 2017 |
[Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats].
Topics: Animals; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Epoprostenol; Hypercapnia; Hyperte | 2011 |
Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats.
Topics: Animals; Biomarkers; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disea | 2012 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; | 2002 |
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Cyclooxygenase 2; Drug Therapy, Combinatio | 2005 |
Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer.
Topics: Angiopoietin-2; Angiopoietins; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; | 2006 |
Varied response of spontaneous tumors to antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Endostatins; Female; Hypoxia; Mammary Neoplasms, Experi | 2005 |